- Home
- PHUN vs ATRA Comparison
PHUN vs ATRA Comparison
Compare PHUN & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | ATRA |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 38.9M |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PHUN | ATRA |
|---|---|---|
| Price | $1.72 | $5.87 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.25 | $6.00 |
| AVG Volume (30 Days) | 91.8K | ★ 297.8K |
| Earning Date | 01-01-0001 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.93 |
| Revenue | $30,883,000.00 | ★ $128,940,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $95.95 | N/A |
| P/E Ratio | ★ N/A | $2.22 |
| Revenue Growth | 15.57 | ★ 1404.02 |
| 52 Week Low | $1.56 | $3.92 |
| 52 Week High | $3.88 | $19.15 |
Technical Indicators
Market Signals| Indicator | PHUN | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.04 | 50.56 |
| Support Level | $1.60 | $4.27 |
| Resistance Level | $2.04 | $7.30 |
| Average True Range (ATR) | 0.08 | 0.82 |
| MACD | -0.00 | 0.29 |
| Stochastic Oscillator | 52.05 | 56.23 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).